Explore stories from Atlantic Canada.
Pro-Palestinian encampment at Dalhousie University - May 13, 2024 | SaltWire #news #halifax #protestLONDON - Patients taking Novo Nordisk's popular Wegovy obesity treatment maintained an average of 10% weight loss after four years on the treatment, the company said on Tuesday.
The data could bolster the company's case as it tries to convince insurers and governments to reimburse Wegovy and deflect notions that it is a lifestyle drug. The new data showing benefits continuing to four years may go some way to negating that argument, he said.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo Nordisk sales up 26% driven by GLP-1s, misses 11% on WegovyNovo Nordisk CEO Lars Jørgensen tells Yahoo Finance the company is confident about a robust GLP-1 sales year despite missing Wall Street estimates.
Read more »
Novo Nordisk raises 2024 outlook as company races to boost output of Wegovy weight-loss drugNovo Nordisk reported better-than-expected first-quarter profits on Thursday as it looks to fend off competition from rival Eli Lilly
Read more »
Novo Quadruples US Patients Starting Wegovy, Boosts OutlookNovo Nordisk A/S is shipping four times more crucial introductory doses of its weight-loss drug Wegovy in the US than at the end of last year, the drugmaker said as it raised its profit and sales outlook.
Read more »
U.S. Senate committee investigates pricing of Novo’s Ozempic and WegovySenator Bernie Sanders sent a letter to Novo’s CEO seeking more information on U.S. prices for the two drugs, which are higher than the prices in other countries
Read more »
US Senate committee investigates pricing of Novo's Ozempic and WegovyExplore stories from Atlantic Canada.
Read more »
US Senate committee investigates pricing of Novo's Ozempic and WegovyExplore stories from Atlantic Canada.
Read more »